logo
Plus   Neg
Share
Email

TUI Backs FY18 EBITA Forecast; Says Trading For Future Seasons Inline With View

Tour operator TUI AG (TUIFF.PK) Thursday announced that its financial year is closing out as expected, with the fourth consecutive year of double digit growth in underlying EBITA since the merger. The company reiterated guidance of at least 10% underlying EBITA growth in FY18.

In its pre-close trading update, the company noted that overall, trading since last update has remained in line with expectations. In Hotels & Resorts, the company benefits from the return in demand for Turkey, North Africa and increased demand for Greece, as well as delivering new openings in South East Asia and the Caribbean. As expected, demand for Spain is normalising from the very high levels seen in recent years.

Looking ahead, Chief Executive of TUI Group, Friedrich Joussen, said, "Whilst at an early stage, trading for future seasons is overall in line with our expectations. Our strong positioning as a leading holiday product provider with own distribution, as well as our balanced portfolio of destinations and markets, mean that we are well positioned to continue to deliver against our growth strategy."

Sales & Marketing trading for Winter 2018/19 is at a relatively early stage, with around one third of the programme sold. Performance is positive overall, with customer volumes up 2%.

TUI Group will issue its Annual Report on December 13.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Pizza Hut's large Original Pan Pizza is now available at locations across the U.S. for $10.99. The fast food chain, a subsidiary of Yum! Brands Inc., said that fans can now get a large Original Pan Pizza with up to three of their favorite toppings, without needing to stretch their wallets. The Original Pan Pizza is a buttery golden-brown color. The U.S. Food and Drug Administration approved the first drug to treat adults and children aged 12 years and older with hypereosinophilic syndrome for six months or longer without another identifiable non-blood related cause of the disease. GlaxoSmithKline's Nucala (mepolizumab) is the first FDA-approved drug in nearly 14 years to treat this group of rare and debilitating blood diseases. Uber has won a legal battle to continue to operate in London, one of its largest markets. The ride-hailing company has been granted an 18-month license to operate in London after overturning the ban on an appeal for the second time. The Westminister Magistrates Court found Uber London Ltd. a "fit and proper" company to run the services in London.
Follow RTT